Development of oncolytic virotherapy using live attenuated poliovirus for human bone and soft tissue sarcomas.

脊髓灰质炎病毒受体CD155是脊髓灰质炎病毒诱导神经细胞死亡所必需的。最近，CD155被证明选择性地表达在某些类型的起源于神经脊的肿瘤细胞上。我们首先检测了CD155在肉瘤细胞系中的表达，发现CD155在所有10个肉瘤细胞系中都有表达。此外，我们还发现减毒活脊髓灰质炎病毒(LAPV)可诱导细胞凋亡。在移植了HT1080的裸鼠中，给予减毒活脊髓灰质炎病毒可抑制肿瘤的生长。接下来，我们评估了43例手术切除的软组织肿瘤中CD155的表达水平。CD155高表达患者的无局部复发生存率明显低于CD155低表达患者，提示LAPV溶瘤治疗可能成为肉瘤治疗的一种新选择。

The poliovirus receptor CD155, is essential for poliovirus to induce cell-death in neural cells. Recently, CD155 has been shown to be selectively expressed on certain types of tumor cells originating from the neural crest. We first examined CD155 expression in sarcoma cell lines, and found the expression of CD155 in all of 10 sarcoma cell lines. Furthermore, we found that live-attenuated polio viruses (LAPV) induced apoptosis. In nude mice transplanted with HT1080, administration of live attenuated poliovirus caused growth suppression of the tumors. Next, the CD155 expression levels in 43 surgically resected soft tissue tumors were evaluated. The local recurrence free survival rate for patients with a high CD155 expression level was significantly poorer compared with that of patients with low CD155 expression levels.These results suggest that oncolytic therapy using a LAPV may represent a new option for the treatment of sarcomas.